CT Residents May Get Refunds in $17.9M Drug Price-Fixing Settlement

Lannett and Bausch Health accused of inflating prices and limiting competition for generic drugs over a decade

Feb. 3, 2026 at 10:15am

Got story updates? Submit your updates here. ›

Two drug companies, Lannett Company Inc. and Bausch Health, have agreed to a $17.85 million settlement after being accused of inflating prices and limiting competition for widely used generic prescription drugs sold nationwide between May 2009 and December 2019. The funds will be distributed to impacted consumers across 48 states and territories after court approval and once a claims process opens.

Why it matters

This settlement aims to return money to residents who were overcharged for necessary medications due to alleged price-fixing and anti-competitive practices by the drug companies. Access to affordable prescription drugs is crucial for many Americans managing serious and chronic illnesses.

The details

Under the agreements, Lannett will pay $13.77 million, while Bausch will pay $4.08 million. Connecticut Attorney General William Tong said the companies' scheme cost families and public health programs millions of dollars. New York Attorney General Letitia James stated the companies hurt patients who rely on affordable medications. Pennsylvania Attorney General Dave Sunday said the settlement helps return money to those who were overcharged and sends a message that drug companies will be held accountable for prioritizing profits over people.

  • The alleged price-fixing and anti-competitive practices occurred between May 2009 and December 2019.
  • The settlement was announced on Monday, February 2, 2026.

The players

Lannett Company Inc.

A generic drugmaker that agreed to pay $13.77 million as part of the settlement.

Bausch Health

A generic drugmaker that agreed to pay $4.08 million as part of the settlement.

William Tong

The Connecticut Attorney General who announced the settlement.

Letitia James

The New York Attorney General who stated the companies hurt patients who rely on affordable medications.

Dave Sunday

The Pennsylvania Attorney General who said the settlement helps return money to those who were overcharged.

Got photos? Submit your photos here. ›

What they’re saying

“Lannett and Bausch both engaged in widespread conspiracies to jack up prices and block competition for generic prescription drugs.”

— William Tong, Connecticut Attorney General

“Access to affordable prescription drugs is a necessity for millions of New Yorkers. After dozens of drug companies colluded behind the scenes to raise costs for consumers, my office is taking action to hold them accountable and get consumers their money back.”

— Letitia James, New York Attorney General

“When companies illegally raise prices and eliminate competition, families, seniors, and patients on fixed incomes pay the price. This settlement helps return money to Pennsylvanians who were overcharged and sends a clear message that drug companies will be held accountable for putting profits over people.”

— Dave Sunday, Pennsylvania Attorney General

What’s next

Anyone who purchased generic prescription drugs manufactured by Lannett or Bausch during the covered period may be eligible for compensation. They can check their eligibility on the settlement's website. The Lannett and Bausch settlements follow earlier multistate agreements totaling $49.1 million with other generic drug manufacturers. The companies also agreed to cooperate with ongoing litigation against pharmaceutical manufacturers and executives, with a trial expected in Hartford, CT, in late 2026.

The takeaway

This settlement highlights the ongoing issue of drug price-fixing and anti-competitive practices in the pharmaceutical industry, which can have a significant impact on the affordability of essential medications for consumers. The actions taken by state attorneys general demonstrate a commitment to holding drug companies accountable and ensuring access to affordable prescription drugs for all.